



S6 Fig. Kaplan-Meier analyses of outcomes by treatment group according to age. Overall survival (A) and progression-free survival (B) of age 18-65 years. Overall survival (C) and progression-free survival (D) of age > 65 years. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; RR-CHOP, intensified the first cycle of rituximab plus eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab.